

## RESOURCES

## PATENTS

## Recent patent applications in the area of peptides

Patent #	Subject	Assignee	Author	Publication date	Status*
WO 9633414	New <i>Leishmania</i> acidic ribosomal P-protein family polypeptide. Used to develop products for diagnosis, detection and protection against <i>Leishmania</i> infections.	Corixa Corp Seattle, WA	Reed SG	10/24/96	A2
WO 9633405	Sample preprocessor for analytical and preparative chemical analysis. Facilitates reliable and reproducible separation of small amounts of analytes.	Mayo Foundation Rochester, MN	Benson LM, Braddock WD, Naylor S, Oda RP, Tomlinson A	10/24/96	A1
WO 9633271	New mutant allele(s) of the <i>BRCA1</i> gene. Useful for assessing susceptibility to inherited breast and ovarian cancer.	University of California	Friedman L, King M, Lynch E, Ostermeyer B, Rowel S, Szabo C, Lee M	10/24/96	A2
WO 9632955	Neuropeptide Y (NPY) analogs. Useful for treating hypertension. Includes amino acids 28–35 of human NPY, but with D-Thr at position 32.	University of East Carolina Greenville, NC	Leonard SA, Nyce JW	10/24/96	A1
US 5567682	Treatment of Alzheimer's disease by intranasal administration of peptide, e.g., peptide T.	Advanced Peptides & Biotechnology Sci Stony Brook, NY	Pert CB	10/22/96	A
WO 9632477	New genes for murine lymphocyte-specific interferon regulatory factor. Used for modulation of lymphocyte activation and proliferation.	Amgen Canada Inc Mississauga, Ontario	Grossman A, Matsuyama T, Richardson CD	10/17/96	A1
WO 9632475	DNA binding proteins with additional zinc finger domain. Having altered specificities, used to regulate gene transcription for production of specific polypeptide(s).	University of Washington Seattle, WA	Cheng C, Young ET	10/17/96	A2
WO 9632412	Peptide(s) that suppress the phosphorylation of $\lambda$ - $\kappa$ - $\beta$ - $\alpha$ . Act as effective antiinflammatory and immunosuppressant agents.	Chugai Seiyaku KK Tokyo	Ishikawa Y, Kuno K, Matsushima K	10/17/96	A1
WO 9632411	Synthetic peptide(s) comprising phosphotyrosine binding domains. Used in diagnosis, screening, and therapy of, e.g., breast cancer.	Kavanaugh WM, Williams LT	Kavanaugh WM, Williams LT	10/17/96	A1
WO 9632410	Novel tetra- and pentapeptide compounds containing two tyrosine residues. Useful as plant growth agents, particularly for monocotyledons such as asparagus, rice plants, and corn.	Kyowa Hakko Kogyo KK Tokyo	Matsubayashi Y, Sakagami Y	10/17/96	A1
WO 9632409	Novel tetra- or pentapeptide containing two sulfated tyrosine residues. Useful as growth promoter for liliaceous plants such as asparagus, lily of the valley, etc.	Kyowa Hakko Kogyo KK Tokyo	Matsubayashi Y, Sakagami Y	10/17/96	A1
WO 9632407	Purifying insulin-like growth factor I using cation exchange, hydrophobic interaction, and reverse phase chromatography matrices.	Cephalon Inc West Chester, PA	Abrams JN, Brierley RA, Hanson JM, Maslanka FC	10/17/96	A1
WO 9632406	Purifying artificial polymer exhibiting reversible inverse temperature transition, specifically bioelastic polymers from complex mixtures of proteins, e.g., those found after expression in host.	Bioelastics Res Ltd UAB Res Found Birmingham, AL	McPherson DT, Urry DW, Xu J	10/17/96	A1
WO 9632140	Artificial veto cells that inhibit or kill specific T cells. For immunotherapy of transplant rejection, inflammation and autoimmune disease, also related cell membranes and lipid-modified polypeptide(s).	TKB Assoc LP	Kaplan DR, Tykocinski ML	10/17/96	A1
WO 9632132	New vaccines for filarial parasite infection(s) comprising C-terminal $\beta$ -tubulin amino acid sequence from a parasite.	McGill University Montreal, Quebec Upjohn Co Kalamazoo, MI	Bughio N, Faubert GM, Geary T, Prichard RK	10/17/96	A1

Source: Derwent Information, McLean, VA. \*The patents in the table are pending. The status of each application is slightly different from country to country. For further details contact Derwent scientific and patent information at Derwent North America, 1420 Spring Hill Road, Suite 525, McLean, VA 22102. Tel: 1 (800) DERWENT (info@derwent.com).